STERO aims to solve an unmet need by using Cannabidiol (CBD), a non-psychotropic component of Cannabis sativa, which has been shown to possess potent immunomodulatory and anti-inflammatory properties in various indications.

Our preliminary results in a phase II trial in GVHD show that CBD administration enhanced the therapeutic effect of steroids or reduced the steroid dosage while maintaining or improving the steroid’s original therapeutic effect.

In all patients treated, the steroid dose administered with CBD was gradually decreased over time. patients refractory to steroid treatment also presented significant improvement to the CBD treatment.

The company plans to validate its concept in various autoimmune diseases.
The company’s product ST-101 is targeted for steroid sparing in multiple indications.

The company’s main focus at the moment is aimed at inflammatory bowel diseases (IBD), steroid dependent Crohn’s disease.
The phase IIa clinical trial started on July 2019.

The company’s next product is aimed for Chronic Urticaria (Hives).
The phase IIa clinical is estimated to commence on Q1 2020.

with more indications in the pipeline.